Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Long-acting bronchodilator such as salmeterol that, when inhaled, does not reach plasma in significant quantities.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data: low molecular weight, low protein binding and long half-life (Yang 2015) makes transfer to milk possible in amounts that could be significant.
Clenbuterol does not alter prolactin levels (Laakmann 1990).
Due to its long half-life, its potential toxicity and illegal uses in veterinary medicine and sports (Woolum 2020) it is not commercialized in several countries. and safer known alternatives are preferred, especially during the neonatal period and in case of prematurity.
Inhaled bronchodilator drugs are preferred because of a lower secretion into breast milk.